Back to Journals » OncoTargets and Therapy » Volume 12

Establishing a detection method for CCNY: a potentially significant clinical investigative marker in NSCLC patients

Authors Ma L, Gu M, Teng Y, Li W

Received 17 July 2018

Accepted for publication 27 December 2018

Published 29 January 2019 Volume 2019:12 Pages 921—932

DOI https://doi.org/10.2147/OTT.S180507

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Manfred Beleut

Peer reviewer comments 2

Editor who approved publication: Dr Sanjay Singh


Li Ma, Meng Gu, Yu Teng, Weiying Li

Department of Cellular and Molecular Biology, Beijing Tuberculosis and Thoracic Tumor Research Institution/Beijing Chest Hospital, Capital Medical University, Beijing 101149, China

Background: CCNY, a novel cyclin family member, plays an increasingly important role in the progression of tumor invasion and metastasis, including lung cancer. However, the clinical significance of CCNY in non-small-cell lung cancer (NSCLC) patients is unknown.
Patients and methods: We prepared CCNY monoclonal antibodies, validated specific peptides by a peptide array, and established a double-antibody sandwich ELISA detection method. Then, we measured CCNY levels in 100 NSCLC patients and 50 healthy controls. A blinded validation was subsequently performed in 399 NSCLC patients and 150 healthy controls.
Results: We successfully prepared two specific mouse anti-human CCNY monoclonal antibodies and established a reliable and stable detection method. In the training set, serum CCNY was markedly increased in the NSCLC patients (P<0.05) with an integrated area under the curve of 0.751. With further analysis of the CCNY levels, there were no differences in age, sex, smoking status, tumor location, histologic subtype, or tumor size, but differences were observed in lymphatic (P<0.001) and distant (P<0.001) metastases in NSCLC patients. The CCNY[+] patients had a shorter survival time and progression-free survival than CCNY[-] patients at 3-year follow-up (P<0.001). The results were confirmed by the validation set.
Conclusion: Our study suggests that CCNY may be useful as a latent tumor marker to facilitate diagnosis and may be an effective indicator of tumor aggressiveness, playing an important role in the prognosis of NSCLC patients.

Keywords: non-small-cell lung cancer, CCNY, peptide array, diagnosis, prognosis, tumor marker

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]